Favorite  |  Set Home
Products > JAK/STAT > JAK > Oclacitinib
Product name : Oclacitinib
Item : CR1869
Price : 50mg, $1050; 100mg, $1485
contact : Send inquiry to: info@acesobio.com
Additional Information :  We offer significant discount for bulky quantity order,Please ask price and availability of other quantities
CAS : 1208319-26-9
 Enlarge Image                   Back
←[Previous Product]              [Next Product]→


Details:
 Chemical Information
M.Wt 337.44 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C15H23N5O2S
CAS No 1208319-26-9
Solubility

DMSO



Biological Activity of Oclacitinib

 

Oclacitinib(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM; not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000 nM).
IC50 value: 10 nM (JAK1) [1]
Target: JAKs
in vitro: Oclacitinib inhibited the function of JAK1-dependent cytokines involved in allergy and inflammation (IL-2, IL-4, IL-6, and IL-13) as well as pruritus (IL-31) at IC50 's ranging from 36 to 249 nm. Oclacitinib had minimal effects on cytokines that did not activate the JAK1 enzyme in cells (erythropoietin, granulocyte/macrophage colony-stimulating factor, IL-12, IL-23; IC50 's > 1000 nm) [1].
in vivo: Dogs were randomized to receive either oclacitinib (0.4-0.6 mg/kg twice daily for 14 days and then once daily for up to 112 days) or an excipient-matched placebo [2].Dogs were randomized to either oclacitinib at 0.4-0.6 mg/kg orally twice daily or an excipient-matched placebo. An enhanced 10 cm visual analog scale (VAS) was used by the owners to assess the severity of pruritus from day 0 to 7 and by veterinarians to assess the severity of dermatitis on days 0 and 7. Dogs could remain on the study for 28 days [3].
 

 

[1]. Gonzales AJ, et al. Oclacitinib (APOQUEL) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014 Aug;37(4):317-24.

[2]. Cosgrove SB, et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013 Dec;24(6):587-97, e141-2.

[3]. Cosgrove SB, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013 Oct;24(5):479-e114.


Related Products :
AZ 960
AZ 960
Price: 10mg, $455; 50mg, $1295; 100mg, $1995; 200mg,$2795
LY 2784544
LY 2784544
Price: 10mg, $265; 50mg, $795; 100mg, $1395; 200mg, $2295
NVP-BSK805
NVP-BSK805
Price: 10mg, $275; 50mg, $695; 100mg, $1295; 200mg, $2295
CYT 387 (CYT11387)
CYT 387 (CYT11387)
Price: 10mg, $125; 50mg, $395; 100mg, $595; 200mg, $995
WP 1066
WP 1066
Price: 10mg, $95, 50mg, $345; 100mg, $595; 200mg, $995
TG 101209
TG 101209
Price: 10mg, $275; 50mg, $765; 100mg, $1295; 200mg, $2195
TG 101348
TG 101348
Price: 10mg, $120; 50mg,$455; 100mg, $745; 200mg,$1295
Lestaurtinib
Lestaurtinib
Price: 5mg, $495; 10mg, $795; 50mg, $1795;